drugset / Trial / NCT05543954
68Ga-FAPI-RGD PET/CT Imaging in the Lung Cancer Patients
Non-randomizedSingle-groupOpen-labelDiagnostic
Summary
Based on the high expression of specific receptors on the surface of diseased tissues and neovascularization, noninvasive targeted molecular imaging can be used to visualize lesions in vitro by combining specific ligands labeled with short half-life isotopes. Lung cancer tissues express fibroblast activating protein FAP, and also have high expression of integrin αVβ3 receptor on the surface of blood vessels. In this study, a novel dual-target imaging agent 68Ga-FAPI-RGD was used for PET/CT imaging of lung cancer.
Timeline
- Start
- 2022-09-03
- Primary completion
- 2025-12-31
- Completion
- 2025-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 18F-FDG | Diagnostic / imaging agent | 3.7 mbq/kg | Intravenous |
| Subject | 18F-FDG | Diagnostic / imaging agent | 5.55 mbq/kg | Intravenous |
| Subject | 68Ga-FAPI-RGD | Diagnostic / imaging agent | 1.8 mbq/kg | Intravenous |
| Subject | 68Ga-FAPI-RGD | Diagnostic / imaging agent | 2.2 mbq/kg | Intravenous |
| Subject | 68Ga-RGD | Diagnostic / imaging agent | 1.8 mbq/kg | Intravenous |
| Subject | 68Ga-RGD | Diagnostic / imaging agent | 2.2 mbq/kg | Intravenous |
| Subject | FAPI GA-68 | Diagnostic / imaging agent | 1.8 mbq/kg | Intravenous |
| Subject | FAPI GA-68 | Diagnostic / imaging agent | 2.2 mbq/kg | Intravenous |